Political tensions around the proposed Save America Act and questions about US institutional strength are back in focus, and that can rattle even seasoned investors. While headlines debate strongman politics and the resilience of courts, media, and the military, some investors are looking again at US blue-chip defensive stocks that may be better suited to handle sharper mood swings in markets. This article walks through 3 stocks from our US Blue-Chip Defensive Stocks screener that appear positively exposed to the current news backdrop and is intended to help you think about where steady dividends and robust balance sheets might matter most when politics dominate the conversation.

Abbott Laboratories (ABT)

Overview: Abbott Laboratories is a global healthcare company that sells a wide range of medical devices, diagnostics, generic medicines and nutrition products, from glucose monitors and heart devices to infant formula and branded pharmaceuticals.

Operations: Abbott Laboratories generates most of its revenue from Medical Devices at about US$22.0b, followed by Diagnostics at about US$9.1b, Nutrition at about US$8.3b, Established Pharmaceutical products at about US$5.7b, with a small contribution from other activities.

Market Cap: US$163.9b

Abbott Laboratories stands out in a politically tense moment because it sells essential healthcare products, has a diversified mix across devices, diagnostics, nutrition and generics, and pays a 2.68% dividend that some investors may value when volatility picks up. Analysts see room between the current share price and their consensus target, yet recent margin pressure, a sharp earnings decline over the past year and high debt mean the story is not risk free. At the same time, progress in cancer diagnostics, diabetes care and AI-enabled cardiology tools, plus a decades long dividend record, give the stock a resilience angle that can look appealing when headlines are dominated by questions about institutional strength and leadership style.

Abbott Laboratories looks like a classic healthcare anchor, but the real story sits in how its essential products, dividend and recent margin pressure fit together. This is exactly what the 4 key rewards and 2 important warning signs starts to reveal

Constellation Brands (STZ)

Overview: Constellation Brands is a large alcoholic beverage company that produces, imports, markets, and sells well known beer, wine, and spirits labels, including Corona, Modelo, Kim Crawford, Robert Mondavi, and Casa Noble across the US and several international markets.

Operations: Constellation Brands generates most of its revenue from Beer at about US$8.3b, with Wine and Spirits contributing about US$0.8b, and around US$9.0b of its US$9.1b sales coming from the US.

Market Cap: US$25.1b

Constellation Brands may warrant closer attention in a politically tense moment because it sits in consumer staples, has a beer portfolio with loyal customers, and has been reshaping its Wine and Spirits arm to focus on higher margin labels and cost savings. Analysts highlight factors such as cash generation, planned share buybacks, and a 2.82% dividend, but also note high debt levels and tariff and cost inflation risks, especially related to Mexican beer and packaging. Management states that brand strength and government affairs work leave the business relatively insulated from whichever party wins the US election. This outlines a trade off between resilience and financial risk that investors may want to understand before considering how Constellation fits into a defensive watchlist.

Constellation Brands appears to be a steady staple stock, yet its cash generation, reshaped Wine and Spirits arm and 2.82% dividend raise bigger questions. Get the full picture in the 6 key rewards and 1 important warning sign

Coca-Cola (KO)

Overview: Coca-Cola is a global beverage company that sells a wide range of nonalcoholic drinks, from its core Coca-Cola soft drinks to water, sports drinks, coffee, tea, juices, dairy and plant based beverages through a network of bottling partners, distributors and retailers in the US and internationally.

Operations: Coca-Cola generates about US$49.3b in revenue from nonalcoholic beverages, with sales spread across regions including North America, Latin America, Asia Pacific and Europe, the Middle East & Africa.

Market Cap: US$355.5b

Coca-Cola tends to get attention when politics turn noisy because its drinks are bought daily around the world, cash generation is strong and the dividend, recently around 2.57%, has a long growth record that some investors treat as bond like income. At the same time, the company is carrying a high level of debt, insiders have been selling stock in recent months and a US$20b tax dispute with the IRS sits in the background as a potential swing factor. Add in a shift toward a more balanced growth model with margins starting to show pressure and the stock trading on a premium P/E. Coca-Cola becomes a classic defensive holding where the quality story is clear but the risk reward trade off deserves a closer look.

Coca-Cola’s premium P/E and bond like dividend are only half the story. The real tension sits between its cash generation, high debt and that US$20b tax dispute, which the analysis report for Coca-Cola starts to unpack just as the risk reward picture gets interesting.

The three blue chip defensive stocks covered here are just a starting point. The full US Blue-Chip Defensive Stocks screener has identified 13 more companies with similarly compelling stories around earnings resilience, dividends and balance sheet strength that you have not seen yet in this article, all captured in the US Blue-Chip Defensive Stocks screener. Use Simply Wall St to analyze and filter these companies by the exact catalysts and narratives discussed here so you can identify the highest conviction ideas that fit your own risk tolerance and income goals.

Take Control of Your Investment Journey

If Abbott Laboratories or any of these companies sound like a great opportunity, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value the ideal entry point. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.

Seeking Alternatives Beyond These Defensives?

Fresh stock ideas can move from quiet accumulation to breakout momentum quickly. By the time headlines catch up, the most attractive entry points can already be past, so it may help to look early.

• Look for emerging trends before they accelerate by scanning curated 51 AI infrastructure stocks that could benefit as demand for data centers and processing capacity builds.
• Explore potential income opportunities by checking a hand picked 8 dividend fortresses that focuses on companies where yield and resilience align.
• Search for under the radar potential by reviewing a carefully filtered 19 high quality undiscovered gems list that may still be overlooked by the broader market.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.